- Company
- Punishment for rebate MD is on the rise
- by Jung, Hye-Jin Dec 19, 2019 06:35am
- A series of tougher penalties rulings against the medical personnel's illegal rebates have been issued. Once caught, the ruling to collect the full rebate collection has become the trend. Analysts say that the justice department increase the level of rebate punishment. Dailypharm's analysis of the major rulings on drug rebates on the
- Policy
- First Samsca generic submits approval application
- by Lee, Tak-Sun Dec 19, 2019 06:34am
- The first generic to follow Korea Otsuka Pharmaceutical’s Samsca (tolvaptan), indicated for treating euvolemic hyponatremia, has submitted an approval application to Korean Ministry of Food and Drug Safety (MFDS). The industry believes Myung In Pharma would be the one to grab the approval as it has been challenging the patent and develo
- Company
- New flu season to spark up another round of competition
- by Kim, Jin-Gu Dec 18, 2019 02:25pm
- The flu season in Korea has just arrived for the year. Korea Centers for Disease Control and Prevention (KCDC) issued a flu warning on November 15. The season is to last until May next year. The new flu season is to start up even more fierce competition in the flu treatment market. The market leader, Tamiflu (oseltamivir) sales has
- Company
- ‘Noltec’, domestic new drug sets a new record
- by Chon, Seung-Hyun Dec 18, 2019 06:25am
- Il Yang's anti-ulcer drug 'Noltec' is breaking a record every day. Continued upward trend after expanding indications, the company benefited from the reflection of impurities from competing drugs. According to UBIST, a drug research agency on the 17th, Noltech's outpatient prescriptions last month increased by 16.7% to &8361;2.9 billion. By No
- Company
- Chong Kun Dang in talks over approved Xofluza
- by Kim, Jin-Gu Dec 18, 2019 06:25am
- Xofluza (baloxavir), a follow-on drug for influenza patient treating Tamiflu (oseltamivir), has been recently approved the Korean health regulator, and is now in talks with Chong Kun Dang Pharmaceutical about the marketing deal in Korea. Korean Ministry of Food and Drug Safety (MFDS) has granted an approval on commercialization of Roch
- Product
- “Lipitor not sold out”, Pfizer clarifies rumors
- by Kim JiEun Dec 18, 2019 06:24am
- Rumors of cholesterol lowering treatment Lipitor tablet going out of stock have been spreading throughout major pharmacies, but its company clarified the rumor is false. Pfizer Upjohn Korea on Tuesday told Daily Pharm that the manufacturing of Lipitor 10 mg tablet (28BLP/ 90BLT) has no issue at the moment. The company’s statement w
- Company
- Oraxol by Hanmi apply US license
- by An, Kyung-Jin Dec 18, 2019 06:24am
- The commercialization of the anti-cancer drug 'Oraxol', a technology exported by Hanmi, is imminent. Hanmi's US partner Athenex unveiled its Phase III clinical results for patients with metastatic breast cancer and announced its intention to approve the FDA in early next year. Some assessments suggest that some indicators, such as gastrointestin
- Policy
- The MFDS plans to collect & test Metformin
- by Lee, Tak-Sun Dec 18, 2019 06:24am
- The Ministry of Food and Drug Safety (the Minister, Eui-Kyung Lee) has decided to collect and inspect commercial distribution items to investigate impurities on Metformin. As a result, the MFDS is preparing a test method with a goal within the year and is conducting a raw material system investigation for the preliminary safety management.
- Company
- Korean companies now having long year-end holiday
- by Lee, Seok-Jun Dec 17, 2019 12:33pm
- The Korean pharmaceutical industry is starting to adopt the long year-end holiday season to wrap up the year around Christmas and to start fresh from the New Year. Boryung Pharmaceutical and other Korean companies are having a long holiday for the first time this year. Multinational pharmaceutical companies are starting their long holiday se
- Policy
- Why did MFDS release its Metformin self-investigation plan?
- by Lee, Tak-Sun Dec 17, 2019 07:20am
- The Ministry of Food and Drug Safety said on the 16th that it is directly investigating the drug 'Metformin', a drug that has been recovered and detected by carcinogen NDMA (N-nitrosodimethylamine) in Singapore. It was the first time that the MFDS announced its own investigation since the Singapore Health and Science Agency announced the
